Board of Directors // Board of Directors – MRM Proteomics
BRENT STERNIG - DIRECTOR (Chair)
Mr. Sternig is the Director of Research Partnerships and Knowledge Mobilization (RPKM) at the University of Victoria. He has over 18 years of experience in the areas of business development, intellectual property protection, technology licensing and new enterprise development. Mr. Sternig manages a portfolio of over 100 patents and has been involved with the creation and governance of over a dozen spin-off companies. He sits on the advisory council for NSERC Pacific's regional operation and for UVic's Innovation Centre for Entrepreneurs. He is a board member for Research Impact and is an active member of the Licensing Executives Society and Association of University Technology Managers. Mr. Sternig earned his Masters of Business Administration from Royal Roads University and his Diploma of Marketing Management from the British Columbia Institute of Technology.
GABE KALMAR, Ph.D. - DIRECTOR
Dr. Kalmar is currently Vice President, Sector Development for Genome British Columbia. Previously he was engaged in strategic consulting activities with several early stage pharmaceutical companies which included overseeing operations, implementing technology development and providing merger and acquisition planning. From 1996 to 2002 Dr. Kalmar held senior management positions with Kinetek Pharmaceuticals Inc., a privately held Vancouver-based biopharmaceutical company that was acquired by QLT in March, 2004. During this time Dr. Kalmar established and managed multiple external collaborations with academics and clinicians in the areas of signal transduction, preclinical studies and technology access. Dr. Kalmar obtained his undergraduate science degree from the University of British Columbia and his PhD in Biology from Simon Fraser University.
CHRISTOPH H. BORCHERS , Ph.D. - CHIEF SCIENTIFIC OFFICER, DIRECTOR
Dr. Borchers is recognized as a pioneer and leading figure in the development of mass spec based methods for protein quantification using Multiple Reaction Monitoring (MRM). He is Full Professor with tenure in the Department of Biochemistry and Microbiology at UVic, is also the Director of the UVic – Genome British Columbia Proteomics Centre and has published more than 150 peer-reviewed papers in scientific journals. His research has centered around the improvement, development and application of proteomics technologies with his major focus on techniques for quantitative targeted proteomics for clinical diagnostics. Dr. Borchers received his B.S., M.S. and Ph.D. from the University of Konstanz, Germany. After his post-doctoral training and employment as a staff scientist at NIEHS/NIH/RTP, NC and he was the director of the Duke – UNC Proteomics Facility and held a faculty position at UNC Medical School in Chapel Hill, NC (2001-2006). Dr. Borchers is also involved in promoting proteomic research and education through his function as HUPO International Council Member, co-leader of the British Columbia Proteomics Network and past President and currently chair of the board and VP of the Canadian National Proteomics Network.
TIM WALZAK, Ph.D. - DIRECTOR
Dr. Walzak has been active in the Canadian research and technology community, working at the interface between research and commercialization, for more than twenty years. Dr. Walzak is currently the Leading Edge Endowment Fund (LEEF) BC Regional Innovation Chair in Sport Technology at Camosun College in Victoria BC, where he was responsible for the establishment of a Sport Innovation Centre in partnership with Canadian Sport Institute Pacific at the Pacific Institute for Sport Excellence. Dr. Walzak is also the Director of Applied Research and Innovation at Camosun, facilitating the expansion of applied research capacity at the college. From 1998 to 2007, Dr. Walzak was the President and CEO of the University of Victoria Innovation and Development Corporation (IDC), the technology transfer office for UVic. More than twelve years of direct experience in developing models to transfer university research to the private sector has allowed Dr. Walzak to establish leadership credentials in a wide range of innovation related activities including basic research, experimental design, development of applications and prototypes, protection of intellectual property, identification of commercialization opportunities and establishment of spin-off companies in a broad range of science and technology areas. He has developed an extensive working knowledge of federal funding mechanisms, most notably NSERC, CFI, NRC IRAP and WED, and has facilitated more than 300 successful partnerships between universities, industry and governments. In the area of early stage company formation, Dr. Walzak has been a partner and founder of a technology consulting business and an instrument manufacturing company. Dr. Walzak has now been actively involved in more than 45 companies started from university-based research activities.
JENNIFER KAUFMAN-SHAW, Ph.D. - DIRECTOR
Dr. Kaufman-Shaw is currently Vice President, Legal Affairs and Intellectual Property at ImStar Therapeutics Inc., a Vancouver-based company founded in 2012 to develop therapeutics for treating amyotrophic lateral sclerosis (ALS). She has over 20 years of legal experience in a biotechnology setting. From 2007 to 2012 Dr. Kaufman-Shaw was Vice President, Intellectual Property at Sirius Genomics Inc. For the 10 years prior to that she led the intellectual property department at QLT Inc., where she was responsible for the strategic management of the patent portfolios for the FDA-approved products PHOTOFRIN, VISUDYNE, ELIGARD and ACZONE as well as various patent litigation matters. Dr. Kaufman-Shaw has participated in numerous licensing, acquisition, joint development and financing transactions. Prior to becoming in-house counsel, she practiced law in the technology group of an Edmonton law firm, concentrating on intellectual property and life sciences. Dr. Kaufman-Shaw obtained both her PhD in biochemistry and her LL.B. from the University of Alberta. She became a registered patent agent in 1997.